Prevention of lymphocyte cell death in sepsis improves survival in mice

R. S. Hotchkiss(Dana-Farber Cancer Institute), Kevin W. Tinsley(University of California, Irvine), Paul E. Swanson(Dana-Farber Cancer Institute), Katherine Chang(University of California, Irvine), Justin Cobb(Dana-Farber Cancer Institute), Timothy G. Buchman(Dana-Farber Cancer Institute), S J Korsmeyer(Dana-Farber Cancer Institute), Irene E. Karl(University of California, Irvine)
Proceedings of the National Academy of Sciences
December 7, 1999
Cited by 457Open Access

Abstract

Sepsis induces extensive lymphocyte apoptosis, a process which may be beneficial to host survival by down-regulating the inflammatory response or, alternatively, harmful by impairing host defenses. To determine the beneficial vs. adverse effects of lymphocyte apoptosis in sepsis, we blocked lymphocyte apoptosis either by N-benzyloxycarbonyl-Val-Ala-Asp(O-methyl) fluoromethyl ketone (z-VAD), a broad-spectrum caspase inhibitor, or by use of Bcl-2 Ig transgenic mice that selectively overexpress the antiapoptotic protein Bcl-2 in a lymphoid pattern. Both z-VAD and Bcl-2 prevented lymphocyte apoptosis and resulted in a marked improvement in survival. z-VAD did not decrease lymphocyte tumor necrosis factor-alpha production. Considered together, these two studies employing different methods of blocking lymphocyte apoptosis provide compelling evidence that immunodepression resulting from the loss of lymphocytes is a central pathogenic event in sepsis, and they challenge the current paradigm that regards sepsis as a disorder resulting from an uncontrolled inflammatory response. Caspase inhibitors may represent a treatment strategy in this highly lethal disorder.


Related Papers

No related papers found

Powered by citation graph analysis